Skip Navigation


IJE Advance Access originally published online on December 12, 2008
International Journal of Epidemiology 2009 38(1):298-303; doi:10.1093/ije/dyn265
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/1/298    most recent
dyn265v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Nüesch, E.
Right arrow Articles by Jüni, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nüesch, E.
Right arrow Articles by Jüni, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2008; all rights reserved.

Commentary: Which meta-analyses are conclusive?

Eveline Nüesch1,2 and Peter Jüni1,2,*

1Institute of Social and Preventive Medicine, University of Bern, Switzerland.
2CTU Bern, Bern University Hospital, Switzerland.

* Corresponding author. Institute of Social and Preventive Medicine, University of Bern, Switzerland. E-mail: juni@ispm.unibe.ch

Accepted 11 November 2008

The first 150 words of the full text of this article appear below.

In 1991, a meta-analysis of seven small-scale trials of intravenous magnesium in a total of 1266 patients with suspected acute myocardial infarction indicated a >50% reduction in the risk of death associated with magnesium (relative risk 0.48, 95% CI 0.26–0.88).1 Yusuf et al. updated this meta-analysis in 19932 to include LIMIT-2,3 at the time the only adequately sized trial, with a power of 80% to detect a moderate to large relative reduction in the risk of death of 33% associated with magnesium. Based on a total of eight trials in 3617 patients with a pooled relative risk of 0.59 (95% CI 0.38–0.91), the authors concluded that ‘intravenous magnesium is a safe, effective, widely practicable and inexpensive intervention that has the potential of making an important impact on the management of patients with myocardial infarction’.2 In 1995, ISIS-4 became available,4 a large-scale trial in 58 050 patients, which had nearly 95% . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?